Cisplatin, the first member of the family of platinum-containing chemotherapeutic agents, was discovered by Barnett Rosenberg in 1965 and approved by the FDA for marketing in 1978. After 30 years of use in the clinic, cisplatin remains a central element of many treatment regimens. Cisplatin is still an irreplaceable component of a regimen that produces high cure rates in even advanced nonseminomatous germ-cell cancers, and is widely used in the treatment of ovarian cancers and other gynecologic cancers, head and neck, and numerous other tumor types. The development of carboplatin has reduced some of the adverse events associated with cisplatin treatment, and the introduction of the DACH platinum compound oxaliplatin has broadened the spectrum of activity of the platinums to include gastro-intestinal cancers, especially colorectal cancer. The clinical importance of this family of drugs continues to drive investigation into how these drugs work and how to improve their efficacy and reduce their toxicity. The papers in this volume were presented in Verona, Italy, during the tenth International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy. The symposium was jointly organized by the Department of Oncology of the Mater Salutis Hospital – Azienda Sanitaria Locale 21 of the Veneto Region – and by the Department of Medicine and Public Health, Section of Pharmacology, the University of Verona. They reflect the vitality of this field and the increasing use of new molecular and cell biologic, genetic, and biochemical tools to identify approaches to further improve their use.

Proceedings of the Fifth International Symposium, held in Abano Terme (Padova), italy, June 29-July 2, 1987

The 7th International Symposium on Platinum and other metal coordination compounds in Cancer Chemotherapy, ISPCC '95, organized by the European Cancer Centre, was held in Amsterdam, the Netherlands, March 1-4, 1995. As with previous ISPCC meetings, the goal of ISPCC '95 was to bring together c1inicians, clinical investigators, scientists, and laboratory workers from many disciplines to promote further collaboration and cooperation in the development of new platinum and other metal coordination compounds as weil as in new ways to use 'c1assical' drugs as cisplatin and carboplatin in the treatment of cancer. Important aspects addressed by experts in the field inc1uded the synthesis and activity of new platinum compounds, the biochemistry and molecular pharrnacology as weil as the c1inical pharrnacology of this c1ass of antineoplastic agents, an overview of current c1inical studies, one special minisymposium on the mechanisms of cell kill of platinum, and one on resistance against platinum compounds. Finally, the current status of development of nonplatinum metal complexes was discussed. This volume contains the contributions of the various speakers at ISPCC '95 and provides an up-to-date and comprehensive overview of this important c1ass of anticancer agents, ranging from synthesis and molecular pharrnacology on one hand to c1inical pharrnacology and cIinical investigations on the other hand. The Organizing Corrunittee and Editors wish to express their gratitude to the contributors to this volume, to the various organizations and pharrnaceutical companies for their generous sponsoring of ISPCC '95, and to the Plenum Publishing Company for their help in producing this volume.

Taken together the data presented in this review, and work by many other investigators, support the notion that DNA excision repair is important in a tumor cell's resistance to platinum compounds. Inhibition of this repair system by combination chemotherapy with the excision repair inhibitors HU and Ara-C produces synergistic cell kills and increased levels and persistance of DNA interstrand crosslinks. The studies with cis-DDP and ~-DDP in combination with UV induced thymine dimers suggest that there may be competition for DNA repair enzymes between the dimer and the platinum lesion. Whether the competing lesion is an intrastrand crosslink, interstrand crosslink, or platinum monoadduct (or all of these lesions) cannot be determined. The similarity between an intrastrand crosslink and a cyclobutane dimer suggests that these lesions may compete for repair. However, the increased peak levels of interstrand crosslinks, and increased persistence of these lesions at later time points suggest that this lesion may also be a substrate for the repair system. These observations may be of clinical relevance. Recently Dr. Kathy Albain of our institution has completed a Phase III I study using a 12 hour pretreatment with HU and Ara-C in patients prior to their cis-DDP therapy. She observed a significant number of responders in this trial (54). She is currently completing a second Phase IIII study substituting IV HU for the oral formulation. We anticipate initiating other clinical trials based upon these observations.

Mark R. Kelley

Effective care of the cancer patient increasingly involves systemic treatment, and as the range of available therapeutic agents continues to expand, the medical oncologist must be fully aware of the rationale for choosing specific drugs and combinations. Textbook of Medical Oncology, 4th edition, is written by a highly acclaimed list of internation

Biomaterials for Precision Cancer Medicine bridges the gap between materials science and medicine, providing insights into novel biomaterial-based treatments for cancer. The book describes the various smart biomaterial-based treatments available, reviewing how they can be designed to target specific tumor types, adapt to changes in the cell microenvironment and offer smart, personalized therapy for different cancer variants, especially those which are drug-resistant. The book provides a materials-focused look at precision cancer medicine, and is thus useful to materials scientists, biomedical engineers, and biomedical scientists – including cancer and genetic specialists – with an interest in alternative cancer therapies. - Reviews the state-of-the-art in precision and translational medicine, setting the scene for the introduction of alternative biomaterial-based therapies - Covers a range of biomaterials for personalized cancer treatment, including polymer-protein conjugates, smart nanoparticles, metal compounds, and more - Addresses preclinical assessment, health risks, challenges and future perspective of precision anti-cancer biomaterials

Environmental pollution is one of the main problems to confront humanity, with the heavy metals occupying a leading role among the most pernicious pollutants. The metals cause cancer and other sicknesses. Their cytotoxic, mutagenic and carcinogenic potentials are not fully understood, and any thorough investigation demands the combined efforts of scientists drawn from many different disciplines. But the effects of heavy metals are not all negative: some, like cis-DDP, and some ruthenium and tin complexes, have antitumour activity. The idea underlying the present work is therefore to present a multidisciplinary perspective on heavy metals in the environment, affording a better understanding of their action on human organisms and health, aiming to make them less polluting and more environmentally friendly.

Intraperitoneal chemotherapy is increasingly being used as first-line treatment for ovarian cancer. Nevertheless, it is difficult for the oncologist to find a definitive text that documents both the fundamental methods required to optimize therapy and the up-to-date results of phase I, II, and III clinical trials. With this in mind, the editors of Intraperitoneal Chemotherapy have assembled a team of highly experienced clinicians and researchers to cover every aspect of the subject. The topics addressed include treatment principles, patient, drug, and catheter selection, administration guidelines, the role of hyperthermia, supportive care requirements, novel drugs, and the most recent results of clinical trials. This book will be an invaluable source of information for both practicing clinical oncologists and oncologists in training.

This is the fourth volume of the eBook Series entitled Topics in Anti-Cancer Research. This volume covers new research as well as updated chapters on topics relevant to modern cancer research published in the journal Recent Patents on Anti-Cancer Drug Discovery. Interesting diverse methods, new technologies and fast developing areas in the field of anti-cancer research are presented. The topics included in the present volume will be of great value to clinicians, scientists and R&D experts aiming to learn more about the latest developments and new alternatives for different types of cancer treatment. The use of gold macro rods and ultrasound for cancer treatment with hyperthermia, obesity associated breast cancer, and the role of cytokines and chemokines pathways in studying cancer immunotherapy are discussed. The mechanism of antibody-drug and antibody-toxin conjugates alongwith clinical trials research, significance of transforming growth factor-beta and urokinase type plasminogen activator in tumorigenesis and reverstol studies in oncohematological disorders are also presented. Other important areas covered include the discovery of novel compounds, drugs and chemotherapeutics in the treatment of lung cancer, biological functions of cell surface nucleolin in cancer, polymeric nanosystems and nanosystem applications used for anticancer drug therapy. Recent advances in development of new potent tubulin inhibitors and structures of molecular hybrids and their actions in different cell lines have also been discussed. All these studies focused are supported by recent associated patents The topics covered in this fourth volume will be of immense interest for those researchers and scientists looking for new techniques, targets, drugs, compounds and drug delivery methods for various types of cancer and its control.